Clinical applications of raltitrexed in colorectal cancer

doi:10.3760/cma.j.issn.1673-422X.2013.12.017

Abstract

PENG Deng-Fu, WANG Yong, HU Bing. Clinical applications of raltitrexed in colorectal cancer[J]. Journal of International Oncology, 2013, 40(12): 933-935.

［1］ International Agency for Research on Cancer. World cancer report 2008. Lyon: WHO, 2008: 374. ［2］ Shahrokni A, Rajebi MR, Saif MW. Toxicity and efficacy of 5fluorouraeil and capecitabine in a patient with TYMS gene polymorphism: a challenge or a dilemma?. Clin Colorectal Cancer, 2009, 8(4): 231234. ［3］ Surmont VF, van Meerbeeck JP. Raltitrexed in mesothelioma. Expert Rev Anticancer Ther, 2011, 11(10): 14811490. ［4］ Popov I, Carrato A, Sobrero A, et al. Raltitrexed (Tomudex) versus standard leucovorinmodulated bolus 5fluorouracil: results from the randomised phase Ⅲ PanEuropean Trial in Adjuvant Colon Cancer 01 (PETACC1). Eur J cancer, 2008, 44(15): 22042211. ［5］ Deboever G, Hitrop N, Cool M, et al. Alternative treatment options in colorectal cancer patients with 5fluorouracil or capecitabineinduced cardiotoxicity. Chin colorectal Cancer, 2013, 12(1): 814. ［6］ Viéitez JM, Valladares M, Peláez I, et al. A randomized phase Ⅱ study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. Invest New Drugs, 2011, 29(5): 10381044. ［7］余嘉文. 雷替曲塞单药二线治疗晚期大肠癌疗效观察. 中国现代药物应用, 2012, 6(4): 1819. ［8］ Khouri C, Guiu B, Cercueil JP, et al. Raltitrexed and oxaliplatin hepatic arterial infusion for advanced colorectal cancer: a retrospective study. Anticancer Drugs, 2010, 21(6): 656661. ［9］王佳蕾, 李进, 秦叔逵, 等. 雷替曲塞或5FU/CF联合奥沙利铂治疗局部晚期或复发转移性结直肠癌多中心、随机、对照Ⅲ期临床试验. 临床肿瘤学杂志, 2012, 17(1): 611. ［10］ Gravalos C, Salut A, Sevilla I, et al. A randomized phase Ⅱ study to compare FOLFOX4 versus TOMOX as firstline chemotherapy for advanced colorectal cancer. Clin Transl Oncol, 2012, 14(8): 606612. ［11］ Paiva CE, Paiva BS, Garita R, et al. Acute coronary syndrome associated with continuous 5Fluorouracil infusion in a patient with metastatic colorectal cancera case report with a discussion on this clinical dilemma. Gastrointest Cancer, 2009, 40(34): 133137. ［12］ Geurs F, Vandewaeter S, Ponette S, et al. Successful and welltolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer. J Gastrointest Cancer, 2008, 39(14): 2628. ［13］ Aparicio J, de las Peas R, Vicent JM, et al. Multicenter phase Ⅰ study of irinotecan plus raltitrexed in patients with 5fluorouracilrefractory advanced colorectal cancer. Oncology, 2002, 63(1): 4247. ［14］ Aparicio J, Vicent JM, Maestu I, et al. Multicenter phase Ⅱ trial evaluating a threeweekly schedule of irinotecan plus raltitrexed in patients with 5fluorouracil refractory advanced colorectal Cancer. Ann Oncol, 2003, 14(7): 11211125. ［15］谢达成, 李宁, 王静珏, 等. 雷替曲塞联合伊立替康2周方案对比FOLFIRI方案二线治疗晚期结直肠癌的疗效观察. 临床肿瘤学杂志, 2013, 18(2): 140143. ［16］ Vakhahova JV, Semenov NN, Dobrova NV, et al. Clinical study of combined use of raltitrexed and xeloda as firstline treatment for patients with metastasizing colorectal cancel. Bull Exp Biol Med, 2008, 145(2): 24925l. ［17］ Garavatta L, Picardi V, Padula GD, et al. Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase Ⅱ study. Acta Oncologica, 2011, 50(8): 11511157. ［18］ Valentini V, Coco C, Minsky BD, et al. Randomized, multicenter, phase Ⅱb study of preoperative chemoradiotherapy in T3 middistal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5fluorouracil + radiotherapy. Int J Radiat Oncol Biol Phys, 2008, 70(2): 403412. ［19］ Wilson KS, Malfair Taylor SC. Raltitrexed: optimism and reality. Expert Opin Drug Metab Toxicol, 2009, 5(11): 14471454. ［20］ Kelly C, Bhuva N, Harrison M, et al. Use of raltitrexed as an alternative to 5fluorouracil and capecitabine in cancer patients with cardiac history. Eur J Cancer, 2013, 49(10): 23032310.

[1]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[5]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[6]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[7]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[8]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[9]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[10]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[11]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[12]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[13]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[14]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[15]	Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46.

Clinical applications of raltitrexed in colorectal cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments